29 November 2010

Produced by: The Royal Bank of Scotland N.V., (India) Office

# Buy

Rs201.00
Price
Rs161.95

# Flashnote

### Analyst

Rahul Jain +91 22 6715 5305 rahul.k.jain@rbs.com

83/84 Sakhar Bhawan, Nariman Point, Mumbai 400 021, India

http://research.rbsm.com

# Sterlite Industries

## Management meet note

We recently met the management of Sterlite Industries and maintain our positive view on the company. We see several triggers for the stock such as i) acquisition of minority government stakes in BALCO and HZL ii) ramp-up of silver output at HZL from 150t to 500t iii) Sale of 3,870MW of power in merchant markets.

### Acquisition of minority stakes

The arbitration over the minority government stake in BALCO (49%) and HZL (29.5%) is over and the judgment is expected anytime. A favorable outcome of arbitration would see substantial value unlocking, in our view and could potentially free up US\$2.4bn of cash for the group. We believe Sterlite's valuation could rise by US\$1.5bn if it completes acquisition of government minority stakes.

### Ramp-up of silver output

Hindustan Zinc produced 87t of silver in 1HFY11 and the company guided for 170t for the full year during the 2QFY11 conference call. The company is targeting 400 plus tonnes by FY12 and 600 tonnes by FY13. The expansion in silver output will be driven by the Sindesar Khurd mine, highly rich in silver. This business will be a significant growth contributor going forward. Since it is still evolving, our current SOTP valuation considers silver to be part of the Zinc business.

### Power sales to surge

- Merchant power sales at Sterlite would rise manifold to 3,870MW following the deferral of aluminum expansions at Vedanta Aluminium operations at Jharsuguda, Orissa and BALCO's operations at Korba, Chhatisgarh. Before the deferral of the aluminium expansions at these locations, power sales were expected at 1200MW, which comprised of 600MW of power from BALCO and 600MW of power from Sterlite Energy (SEL). With the change in plans, an additional 2400MW of power (1800MW additional from SEL and 600MW from BALCO) would be available for sale in merchant markets. This would lead to a sharp jump in power sold from 154MW in FY10 to an estimated 449MW in FY11 and 2200MW in FY12. We estimate that by FY13, the energy segment will contribute 10% of net revenues and 20% of EBITDA.
- SEL IPO: Sterlite is also looking at value unlocking at SEL through an IPO, which may be launched once market conditions are appropriate.

(Continued on page 2)

### SOTP

				Attributable
	<b>EBITDA</b>	Multiple	EV	EV
Entity	(Rs bn)	(X)	(Rs bn)	(Rs/share)
Bauxite and aluminium (Balco)	17	6.3	108	16
Alumina refining and aluminium smelting (VAL)				7
Copper smelting (Sterlite Inds.)	11	6.3	70	21
Copper mining (Copper mines of Tasmania)				2
Zinc mining and smelting (HZN)	72	6.3	452	87
2400MW power generation (SEL)				25
Total enterprise value				158
Less: net debt (HZN, Sterlite Inds.)				-43
Attributable market capitalization				201
Target price (Rs/share)				201

Source: RBS estimates

Important disclosures can be found in the Disclosures Appendix.

- Aluminium: The 325kt Korba III smelter and 1.25mt Jharsuguda II smelter projects have been deferred by 18-24 months. Balco has been exclusively allocated the Durgapur-II/Taraimar block in Chattisgarh. Balco has also got coal linkage for the first 600MW and it has applied for the remaining units.
- Copper smelting: The Supreme Court stay on the Tuticorin plant closure is effective till the
  next hearing which is in mid-December. We note that globally, the copper smelting business
  continues to be weighted down by shrinking Tc/Rc charges and we estimate a contribution of
  Rs21 per share of Sterlite from the copper smelting business.

Rsm	FY09A	FY10A	FY11F	FY12F	FY13F
Revenue	214484	244103	290346	382433	490479
Cost of sales	-163473	-182261	-207080	-254063	-332644
Operating costs	n/a	n/a	n/a	n/a	n/a
EBITDA	51011	61843	83266	128370	157835
DDA & Impairment (ex gw)	-7007	-7498	-10560	-17392	-23307
EBITA	44004	54345	72706	110978	134528
Goodwill (amort/impaired)	n/a	n/a	n/a	n/a	n/a
EBIT	44004	54345	72706	110978	134528
Net interest	-3973	-3424	-8471	-11938	-10499
Associates (pre-tax)	n/a	n/a	n/a	n/a	n/a
Forex gain / (loss)	n/a	n/a	n/a	n/a	n/a
Exceptionals (pre-tax)	553.1	-2970	0.00	0.00	0.00
Other pre-tax items	17573	18469	17395	19899	23319
Reported PTP	58158	66420	81630	118939	147348
Taxation	-8550	-12330	-17146	-25380	-30297
Minority interests	-12671	-17241	-20028	-25746	-33443
Exceptionals (post-tax)	n/a	n/a	n/a	n/a	n/a
Other post-tax items	-1536	587.7	216.4	3018	7233
Reported net profit	35400	37437	44672	70831	90841
Normalised Items Excl. GW	553.1	-2970	0.00	0.00	0.00
Normalised net profit	34847	40407	44672	70831	90841

Source: Company data, RBS forecasts	year to Mar
-------------------------------------	-------------

Rsm	FY09A	FY10A	FY11F	FY12F	FY13F
Cash & market secs (1)	55048	33378	28833	76859	134228
Other current assets	61312	141737	175028	189274	209740
Tangible fixed assets	172104	233500	316917	316811	301451
Intang assets (incl gw)	n/a	n/a	n/a	n/a	n/a
Oth non-curr assets	162061	203045	217648	252648	277556
Total assets	450526	611659	738427	835592	922975
Short term debt (2)	n/a	n/a	n/a	n/a	n/a
Trade & oth current liab	42051	49319	50254	56460	66242
Long term debt (3)	70135	92600	131298	131603	100005
Oth non-current liab	14078	15526	17772	21872	25963
Total liabilities	126264	157445	199325	209935	192209
Total equity (incl min)	324262	454214	539102	625658	730766
Total liab & sh equity	450526	611659	738427	835592	922975
Net debt	15087	59222	102465	54744	-34224

Source: Company data, RBS forecasts	year ended Mar

Rsm	FY09A	FY10A	FY11F	FY12F	FY13F
EBITDA	51011	61843	83266	128370	157835
Change in working capital	13636	-8487	-16143	-3181	-9701
Net interest (pd) / rec	12801	12279	0.00	0.00	0.00
Taxes paid	-8522	-11549	-14360	-22071	-25056
Other oper cash items	-1835	-5459	-9594	17528	14492
Cash flow from ops (1)	67090	48627	43169	120646	137570
Capex (2)	-40095	-61819	-81027	-29823	-10500
Disposals/(acquisitions)	0.00	0.00	0.00	0.00	0.00
Other investing cash flow	-4227	-102169	-30100	-35100	-30100
Cash flow from invest (3)	-44322	-163989	-111127	-64923	-40600
Incr / (decr) in equity	0.00	76248	31262	0.00	0.00
Incr / (decr) in debt	12762	21795	38698	305.1	-31598
Ordinary dividend paid	-3938	-4352	-6547	-8002	-8002
Preferred dividends (4)	n/a	n/a	n/a	n/a	n/a
Other financing cash flow	n/a	n/a	n/a	n/a	n/a
Cash flow from fin (5)	8824	93691	63413	-7697	-39601
Forex & disc ops (6)	-1080	0.00	0.00	0.00	0.00
Inc/(decr) cash (1+3+5+6)	30513	-21671	-4544	48026	57369
Equity FCF (1+2+4)	26996	-13193	-37858	90823	127070

Lines in bold can be derived from the immediately preceding lines. Source: Company data, RBS forecasts

year to Mar

### Recommendation structure

Absolute performance, short term (trading) recommendation: A Trading Buy recommendation implies upside of 5% or more and a Trading Sell indicates downside of 5% or more. The trading recommendation time horizon is 0-60 days. For Australian coverage, a Trading Buy recommendation implies upside of 5% or more from the suggested entry price range, and a Trading Sell recommendation implies downside of 5% or more from the suggested entry price range. The trading recommendation time horizon is 0-60 days.

Absolute performance, long term (fundamental) recommendation: The recommendation is based on implied upside/downside for the stock from the target price and, except as follows, only reflects capital appreciation. A Buy/Sell implies upside/downside of 10% or more and a Hold less than 10%. For research produced by Nedbank Capital, a Buy implies upside in excess of 20%, A Sell implies an expected return less than 10%, and a Hold implies a return between 10% and 20%. For UK-based Investment Funds research, the recommendation structure is not based on upside/downside to the target price. Rather it is the subjective view of the analyst based on an assessment of the resources and track record of the fund management company. For research produced by Nedbank Capital and for research on Australian listed property trusts (LPT) or real estate investment trusts (REIT), the recommendation is based upon total return, ie, the estimated total return of capital gain, dividends and distributions received for any particular stock over the investment horizon.

Performance parameters and horizon: Given the volatility of share prices and our pre-disposition not to change recommendations frequently, these performance parameters should be interpreted flexibly. Performance in this context only reflects capital appreciation and the horizon is 12 months.

Market or sector view: This view is the responsibility of the strategy team and a relative call on the performance of the market/sector relative to the region. Overweight/Underweight implies upside/downside of 10% or more and Neutral implies less than 10% upside/downside.

Target price: The target price is the level the stock should currently trade at if the market were to accept the analyst's view of the stock and if the necessary catalysts were in place to effect this change in perception within the performance horizon. In this way, therefore, the target price abstracts from the need to take a view on the market or sector. If it is felt that the catalysts are not fully in place to effect a re-rating of the stock to its warranted value, the target price will differ from 'fair' value.

### Distribution of recommendations

The tables below show the distribution of recommendations (both long term and trading). The first column displays the distribution of recommendations globally and the second column shows the distribution for the region. Numbers in brackets show the percentage for each category where there is an investment banking relationship. These numbers include recommendations produced by third parties with which RBS has joint ventures or strategic alliances.

# Global total (IB%) Asia Pacific total (IB%) (IB%) Buy 710 (0) 446 (0) Add 0 (0) 0 (0)

Long term recommendations (as at 29 Nov 2010)

 Buy
 710 (0)
 446 (0)

 Add
 0 (0)
 0 (0)

 Hold
 445 (0)
 243 (0)

 Reduce
 0 (0)
 0 (0)

 Sell
 111 (0)
 69 (0)

 Total (IB%)
 1266 (0)
 758 (0)

Source: RBS

Trading	recommendations	(ac at 20	Nov 2010)
Traumu	recommendations	(as at 29	NOV ZU IU)


	Global total (IB%)	Asia Pacific total (IB%)
Trading Buy	1 (0)	1 (0)
Trading Sell Total (IB%)	0 (0) 1 (0)	0 (0) 1 (0)

Source: RBS

### Valuation and risks to target price

Sterlite Industries (RIC: STRL.BO, Rec: Buy, CP: Rs161.95, TP: Rs201.00): We value Sterlite based on a sum-of-the-parts valuation methodology. We value the individual assets separately, valuing the base metals business on an EV/EBITDA multiple, based on average peer group valuations, and the power business power business on a DCF. Key risks would be delays in project commissioning, an unfavourable arbitration outcome to Sterlite's bid to acquire minority government holdings and a weakening in base metal prices.

### Sterlite Industries coverage data (STRL.BO, STLT IN)



Rahul Jain started covering this stock on 24 Sep 10. Moved to new recommendation structure between 1 November 2005 and 31 January 2006. Source: RBS

### **Trading recommendation history**

Date	Rec	Analyst
n/a	n/a	n/a

Source: RBS

### Price perf (at Close 29 Nov 2010)

	(1M)	(3M)	(12M)
Price (Rs)	168.6	152.1	207.7
Absolute (%)	-4.0	6.5	-22.0
Rel market (%)	-0.9	-1.2	-33.2
Rel sector (%)	-1.4	0.0	-17.7

Source: Bloomberg Market: Sensex Sector: Nonferrous Metals

### Regulatory disclosures

None

### Global disclaimer

© Copyright 2010 The Royal Bank of Scotland N.V. and affiliated companies ("RBS"). All rights reserved.

This material was prepared by the legal entity named on the cover or inside cover page. It is provided for informational purposes only and does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. While based on information believed to be reliable, no guarantee is given that it is accurate or complete. While we endeavour to update on a reasonable basis the information and opinions contained herein, there may be regulatory, compliance or other reasons that prevent us from doing so. The opinions, forecasts, assumptions, estimates, derived valuations and target price(s) contained in this material are as of the date indicated and are subject to change at any time without prior notice. The investments referred to may not be suitable for the specific investment objectives, financial situation or individual needs of recipients and should not be relied upon in substitution for the exercise of independent judgement. The stated price of any securities mentioned herein is as of the date indicated and is not a representation that any transaction can be effected at this price. Neither RBS nor other persons shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way from the information contained in this material. This material is for the use of intended recipients only and the contents may not be reproduced, redistributed, or copied in whole or in part for any purpose without RBS's prior express consent. In any jurisdiction in which distribution to private/retail customers would require registration or licensing of the distributor which the distributor does not currently have, this document is intended solely for distribution to professional and institutional investors.

Australia: Any report referring to equity securities is distributed in Australia by RBS Equities (Australia) Limited (ABN 84 002 768 701, AFS Licence 240530), a participant of the ASX Group. Any report referring to fixed income securities is distributed in Australia by The Royal Bank of Scotland NV (Australia Branch) (ABN 84 079 478 612, AFS Licence 238266). Australian investors should note that this document was prepared for wholesale investors only.

Canada: The securities mentioned in this material are available only in accordance with applicable securities laws and many not be eligible for sale in all jurisdictions. Persons in Canada requiring further information should contact their own advisors.

EEA: This material constitutes "investment research" for the purposes of the Markets in Financial Instruments Directive and as such contains an objective or independent explanation of the matters contained in the material. Any recommendations contained in this document must not be relied upon as investment advice based on the recipient's personal circumstances. In the event that further clarification is required on the words or phrases used in this material, the recipient is strongly recommended to seek independent legal or financial advice.

Denmark: Royal Bank of Scotland N.V. is authorised and regulated in the Netherlands by De Netherlandsche Bank. In addition, Royal Bank of Scotland N.V. Danish branch is subject to local supervision by Finanstilsynet, The Danish Financial Supervisory Authority.

Hong Kong: This document is being distributed in Hong Kong by, and is attributable to, RBS Asia Limited which is regulated by the Securities and Futures Commission of Hong Kong. India: Shares traded on stock exchanges within the Republic of India may only be purchased by different categories of resident Indian investors, Foreign Institutional Investors registered with The Securities and Exchange Board of India ("SEBI") or individuals of Indian national origin resident outside India called Non Resident Indians ("NRIs"). Any recipient of this document wanting additional information or to effect any transaction in Indian securities or financial instrument mentioned herein must do so by contacting a representative of RBS Equities (India) Limited. RBS Equities (India) Limited is a subsidiary of The Royal Bank of Scotland N.V..

Italy: Persons in Italy requiring further information should contact The Royal Bank of Scotland N.V. Milan Branch.

Japan: This report is being distributed in Japan by RBS Securities Japan Limited to institutional investors only.

South Korea: This document is being distributed in South Korea by, and is attributable to, RBS Asia Limited (Seoul) Branch which is regulated by the Financial Supervisory Service of South Korea

Malaysia: RBS research, except for economics and FX research, is not for distribution or transmission into Malaysia.

Netherlands: the Authority for the Financial Markets ("AFM") is the competent supervisor.

Russia: This Material is distributed in the Russian Federation by RBS and "The Royal Bank of Scotland" ZAO (general banking license No. 2594 issued by the Central Bank of the Russian Federation, registered address: building 1, 17 Bolshaya Nikitskaya str., Moscow 125009, the Russian Federation), an affiliate of RBS, for information purposes only and is not an offer to buy or subscribe or otherwise to deal in securities or other financial instruments, or to enter into any legal relations, nor as investment advice or a recommendation with respect to such securities or other financial instruments. This Material does not have regard to the specific investment purposes, financial situation and the particular business needs of any particular recipient. The investments and services contained herein may not be available to persons other than 'qualified investors" as this term is defined in the Federal Law "On the Securities Market"

Singapore: Any material in connection with equity securities is distributed in Singapore by The Royal Bank of Scotland Asia Securities (Singapore) Pte Limited ("RBS Asia Securities") (RCB Regn No. 198703346M). Without prejudice to any of the foregoing disclaimers, this material and the securities, investments or other financial instruments referred to herein are not in any way intended for, and will not be available to, investors in Singapore unless they are institutional investors (as defined in Section 4A(1) of the Securities and Futures Act (Cap. 289) of Singapore ("SFA") or relevant persons falling within Section 275 of the SFA and in accordance with the conditions specified therein or otherwise fall within the circumstances under Section 275 of the SFA. Further, without prejudice to any of the foregoing disclaimers, where this material is distributed to accredited investors or expert investors as defined in Regulation 2 of the Financial Advisers Regulations ("FAR") of the Financial Advisers Act (Cap. 110) of Singapore ("FAA"), RBS Asia Securities is exempted by Regulation 35 of the FAR from the requirements in Section 36 of the FAA mandating disclosure of any interest in securities referred to in this material, or in their acquisition or disposal. Recipients who do not fall within the description of persons under Regulation 49 of the Securities and Futures (Licensing and Conduct of Business) Regulations or Regulations 35 of the Financial Advisor prior to taking any investment decision based on this document or for any necessary explanation of its contents.

Thailand: Pursuant to an agreement with Asia Plus Securities Public Company Limited (APS), reports on Thai securities published out of Thailand are prepared by APS but distributed outside Thailand by RBS Bank NV and affiliated companies. Responsibility for the views and accuracy expressed in such documents belongs to APS.

Turkey: The Royal Bank of Scotland N.V. is regulated by Banking Regulation and Supervision Authority (BRSA)

UAE and Qatar: This report is produced by The Royal Bank of Scotland N.V and is being distributed to professional and institutional investors only in the United Arab Emirates and Qatar in accordance with the regulatory requirements governing the distribution of investment research in these jurisdictions.

Dubai International Financial Centre: This material has been prepared by The Royal Bank of Scotland N.V. and is directed at "Professional Clients" as defined by the Dubai Financial Services Authority (DFSA). No other person should act upon it. The financial products and services to which the material relates will only be made available to customers who satisfy the requirements of a "Professional Client". This Document has not been reviewed or approved by the DFSA.

Qatar Financial Centre: This material has been prepared by The Royal Bank of Scotland N.V. and is directed solely at persons who are not "Retail Customer" as defined by the Qatar Financial Centre Regulatory Authority. The financial products and services to which the material relates will only be made available to customers who satisfy the requirements of a "Business Customer" or "Market Counterparty".

United States of America: This document is intended for distribution only to "major institutional investors" as defined in Rule 15a-6 under the U.S. Exchange Act of 1934 as amended (the "Exchange Act"), and may not be furnished to any other person in the United States. Each U.S. major institutional investor that receives these materials by its acceptance hereof represents and agrees that it shall not distribute or provide these materials to any other person. Any U.S. recipient of these materials that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this document, should contact and place orders solely through a registered representative of RBS Securities Inc., 600 Washington Boulevard, Stamford, CT, USA. Telephone: +1 203 897 2700. RBS Securities Inc. is an affiliated broker-dealer registered with the U.S. Securities and Exchange Commission under the Exchange Act, and a member of the Securities Investor Protection Corporation (SIPC) and the Financial Industry Regulatory Authority (FINRA).

- Material means all research information contained in any form including but not limited to hard copy, electronic form, presentations, e-mail, SMS or WAP.

The research analyst or analysts responsible for the content of this research report certify that: (1) the views expressed and attributed to the research analyst or analysts in the research report accurately reflect their personal opinion(s) about the subject securities and issuers and/or other subject matter as appropriate; and, (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views contained in this research report. On a general basis, the efficacy of recommendations is a factor in the performance appraisals of analysts.

For a discussion of the valuation methodologies used to derive our price targets and the risks that could impede their achievement, please refer to our latest published research on those stocks at research.rbsm.com.

Disclosures regarding companies covered by us can be found on our research website at research.rbsm.com

Our policy on managing research conflicts of interest can be found at https://research.rbsm.com/Disclosure/Disclosure.AspX?MI=2.

Should you require additional information please contact the relevant research team or the author(s) of this report.